Literature DB >> 27076642

Roles of Capsid-Interacting Host Factors in Multimodal Inhibition of HIV-1 by PF74.

Akatsuki Saito1, Damien Ferhadian1, Gregory A Sowd2, Erik Serrao2, Jiong Shi3, Upul D Halambage3, Samantha Teng1, Juan Soto1, Mohammad Adnan Siddiqui1, Alan N Engelman2, Christopher Aiken3, Masahiro Yamashita4.   

Abstract

UNLABELLED: The viral capsid of HIV-1 interacts with a number of host factors to orchestrate uncoating and regulate downstream events, such as reverse transcription, nuclear entry, and integration site targeting. PF-3450074 (PF74), an HIV-1 capsid-targeting low-molecular-weight antiviral compound, directly binds to the capsid (CA) protein at a site also utilized by host cell proteins CPSF6 and NUP153. Here, we found that the dose-response curve of PF74 is triphasic, consisting of a plateau and two inhibitory phases of different slope values, consistent with a bimodal mechanism of drug action. High PF74 concentrations yielded a steep curve with the highest slope value among different classes of known antiretrovirals, suggesting a dose-dependent, cooperative mechanism of action. CA interactions with both CPSF6 and cyclophilin A (CypA) were essential for the unique dose-response curve. A shift of the steep curve at lower drug concentrations upon blocking the CA-CypA interaction suggests a protective role for CypA against high concentrations of PF74. These findings, highlighting the unique characteristics of PF74, provide a model in which its multimodal mechanism of action of both noncooperative and cooperative inhibition by PF74 is regulated by interactions of cellular proteins with incoming viral capsids. IMPORTANCE: PF74, a novel capsid-targeting antiviral against HIV-1, shares its binding site in the viral capsid protein (CA) with the host factors CPSF6 and NUP153. This work reveals that the dose-response curve of PF74 consists of two distinct inhibitory phases that are differentially regulated by CA-interacting host proteins. PF74's potency depended on these CA-binding factors at low doses. In contrast, the antiviral activity of high PF74 concentrations was attenuated by cyclophilin A. These observations provide novel insights into both the mechanism of action of PF74 and the roles of host factors during the early steps of HIV-1 infection.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27076642      PMCID: PMC4886767          DOI: 10.1128/JVI.03116-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  70 in total

1.  Structural basis of HIV-1 capsid recognition by PF74 and CPSF6.

Authors:  Akash Bhattacharya; Steven L Alam; Thomas Fricke; Kaneil Zadrozny; Jaroslaw Sedzicki; Alexander B Taylor; Borries Demeler; Owen Pornillos; Barbie K Ganser-Pornillos; Felipe Diaz-Griffero; Dmitri N Ivanov; Mark Yeager
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-17       Impact factor: 11.205

2.  Complementary Assays Reveal a Low Level of CA Associated with Viral Complexes in the Nuclei of HIV-1-Infected Cells.

Authors:  Amy E Hulme; Z Kelley; Deirdre Foley; Thomas J Hope
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

Review 3.  HIV-1 gag: an emerging target for antiretroviral therapy.

Authors:  Philip R Tedbury; Eric O Freed
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 4.  HIV-1 uncoating: connection to nuclear entry and regulation by host proteins.

Authors:  Zandrea Ambrose; Christopher Aiken
Journal:  Virology       Date:  2014-02-20       Impact factor: 3.616

5.  Target cell type-dependent modulation of human immunodeficiency virus type 1 capsid disassembly by cyclophilin A.

Authors:  Yuan Li; Alak Kanti Kar; Joseph Sodroski
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

Review 6.  Revisiting HIV-1 uncoating.

Authors:  Nathalie Arhel
Journal:  Retrovirology       Date:  2010-11-17       Impact factor: 4.602

7.  Quantitative microscopy of functional HIV post-entry complexes reveals association of replication with the viral capsid.

Authors:  Ke Peng; Walter Muranyi; Bärbel Glass; Vibor Laketa; Stephen R Yant; Luong Tsai; Tomas Cihlar; Barbara Müller; Hans-Georg Kräusslich
Journal:  Elife       Date:  2014-12-17       Impact factor: 8.140

Review 8.  A novel method for determining the inhibitory potential of anti-HIV drugs.

Authors:  Lin Shen; S Alireza Rabi; Robert F Siliciano
Journal:  Trends Pharmacol Sci       Date:  2009-12       Impact factor: 14.819

9.  Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells.

Authors:  Masahiro Yamashita; Omar Perez; Thomas J Hope; Michael Emerman
Journal:  PLoS Pathog       Date:  2007-10-26       Impact factor: 6.823

10.  CPSF6 defines a conserved capsid interface that modulates HIV-1 replication.

Authors:  Amanda J Price; Adam J Fletcher; Torsten Schaller; Tom Elliott; KyeongEun Lee; Vineet N KewalRamani; Jason W Chin; Greg J Towers; Leo C James
Journal:  PLoS Pathog       Date:  2012-08-30       Impact factor: 6.823

View more
  44 in total

1.  Exploring Modifications of an HIV-1 Capsid Inhibitor: Design, Synthesis, and Mechanism of Action.

Authors:  Jimmy P Xu; Ashwanth C Francis; Megan E Meuser; Marie Mankowski; Roger G Ptak; Adel A Rashad; Gregory B Melikyan; Simon Cocklin
Journal:  J Drug Des Res       Date:  2018-08-13

2.  A Novel Phenotype Links HIV-1 Capsid Stability to cGAS-Mediated DNA Sensing.

Authors:  Mohammad Adnan Siddiqui; Akatsuki Saito; Upul D Halambage; Damien Ferhadian; Douglas K Fischer; Ashwanth C Francis; Gregory B Melikyan; Zandrea Ambrose; Christopher Aiken; Masahiro Yamashita
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

3.  PF74 Inhibits HIV-1 Integration by Altering the Composition of the Preintegration Complex.

Authors:  Muthukumar Balasubramaniam; Jing Zhou; Amma Addai; Phillip Martinez; Jui Pandhare; Christopher Aiken; Chandravanu Dash
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

4.  Distinct functions of diaphanous-related formins regulate HIV-1 uncoating and transport.

Authors:  Michael Keegan Delaney; Viacheslav Malikov; Qingqing Chai; Guangyuan Zhao; Mojgan H Naghavi
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-31       Impact factor: 11.205

5.  CA Mutation N57A Has Distinct Strain-Specific HIV-1 Capsid Uncoating and Infectivity Phenotypes.

Authors:  Douglas K Fischer; Akatsuki Saito; Christopher Kline; Romy Cohen; Simon C Watkins; Masahiro Yamashita; Zandrea Ambrose
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

6.  Cell Type-Dependent Escape of Capsid Inhibitors by Simian Immunodeficiency Virus SIVcpz.

Authors:  Augustin Penda Twizerimana; Rachel Scheck; Daniel Becker; Zeli Zhang; Marianne Wammers; Leandro Avelar; Marc Pflieger; Dieter Häussinger; Thomas Kurz; Holger Gohlke; Carsten Münk
Journal:  J Virol       Date:  2020-11-09       Impact factor: 5.103

Review 7.  Capsid-Dependent Host Factors in HIV-1 Infection.

Authors:  Masahiro Yamashita; Alan N Engelman
Journal:  Trends Microbiol       Date:  2017-05-18       Impact factor: 17.079

8.  Capsid-CPSF6 Interaction Is Dispensable for HIV-1 Replication in Primary Cells but Is Selected during Virus Passage In Vivo.

Authors:  Akatsuki Saito; Matthew S Henning; Erik Serrao; Brittany N Dubose; Samantha Teng; Jing Huang; Xiangming Li; Namiko Saito; Saumendra Prasad Roy; Mohammad Adnan Siddiqui; Jinwoo Ahn; Moriya Tsuji; Theodora Hatziioannou; Alan N Engelman; Masahiro Yamashita
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

9.  Dominant Negative MA-CA Fusion Protein Is Incorporated into HIV-1 Cores and Inhibits Nuclear Entry of Viral Preintegration Complexes.

Authors:  Jordan Anderson-Daniels; Parmit K Singh; Gregory A Sowd; Wen Li; Alan N Engelman; Christopher Aiken
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

10.  HIV-1 Activation of Innate Immunity Depends Strongly on the Intracellular Level of TREX1 and Sensing of Incomplete Reverse Transcription Products.

Authors:  Swati Kumar; James H Morrison; David Dingli; Eric Poeschla
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.